# Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

> **NCT07421011** · PHASE1 · RECRUITING · sponsor: **Valenta Pharm JSC** · enrollment: 36 (estimated)

## Conditions studied

- Irritable Bowel Syndrome
- Gallstone Disease
- GERD
- Biliary Dyskinesia
- Postcholecystectomy Syndrome

## Interventions

- **DRUG:** Trimedat®

## Key facts

- **NCT ID:** NCT07421011
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421011, "Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07421011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*